Full-Range IHC Raw Material Supplier One-Stop IHC Raw Material Solutions

Covering primary and secondary antibodies plus supporting reagents, we deliver complete IHC raw material solutions for hospital pathology labs, research institutes, and IVD partners.

Learn More

230+ Self-Developed Pathology-Grade Antibodies Validated with Leading Pathology Experts

Pathology-grade primary antibodies validated across multiple tissues and platforms, co-evaluated with industry pathology experts, compatible with mainstream staining instruments, with datasheets and free trial samples available.

Learn More

Self-Developed Spherical Polymer HRP Secondary Antibody Smaller Size, Higher Binding Efficiency

Our spherical multi-polymer HRP labeling system offers a smaller molecular footprint and higher binding rates, with synchronized mouse/rabbit amplification for improved IHC staining sensitivity and stability.

Learn More

Antigen preparation

Mouse or rabbit immunization

PBMC isolation

IgG+ cell separation

scFv gene amplification

Phage display library construction

High-throughput screening

Recombinant antibody engineering & production

IHC validation

Featured Products

Sales-leading, Clinically Validated

P16

P16 is a cell cycle negative regulatory protein that can competitively bind and inhibit cyclin dependent kinase 4 (CDK4), which will obstruct the production of phosphorylated retinoblastoma protein (pRb), thereby preventing cells from entering the S phase. Some research found that human papilloma virus (HPV) can reduce pRb activity to eliminate negative feedback inhibition, which will induce high expression of P16 and cause cell cycle disorder, thereby initiating cellular carcinogenesis. Therefore, P16 is mainly used as a diagnostic indicator for high-risk cervical HPV infection. For example, P16 is diffusely strongly expressed in HSIL but locally weakly expressed in LSIL, which makes it become one of the differential markers. Meanwhile, the combination of P16 and Ki-67 has important guiding significance for the diagnosis, treatment, and prognosis of cervical cancer. In addition, the loss of P16 is related to poor prognosis of various tumors such as gastric cancer, colorectal cancer, and thyroid cancer.

MY001 | MyM1-p16

View Details

Ki-67

Ki-67 is a DNA binding protein widely present in various proliferating cells. It is absent in the G0 phase, but begins to be expressed in the G1 phase, reaches its peak in the M phase, and sharply decreases in the late phases. Some scholars speculated that Ki-67 can maintain chromosomes separated in the early stage its huge molecular weight and electric potential difference, while down-regulate in the later stage to aggregate chromosomes. Meanwhile, Ki-67 can participate in the occurrence and development of tumors, but the specific mechanism is still unclear, which may be related to the formation of heterochromatin or the maintenance of cancer cell transcription programs. In clinical practice, Ki-67 is the most widely used cell proliferation biomarker at present, and the diffusion index based on Ki-67 staining has also become a necessary prognostic evaluation indicator for lung cancer, gastric cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, glioma, neuroendocrine neoplasm, etc. In addition, inhibiting Ki-67 expression is considered as a promising tumor treatment method, including chemotherapy, radiotherapy, RNA interference, and promoter controlled cancer gene therapy.

MY004 | MyM1-Ki67

View Details

Estrogen Receptor α

Estrogen receptor α (ERα) is a subtype of estrogen nuclear receptor, widely existing in breast, uterus, testis and other organs. Its binding with estrogen can regulate gene transcription, thereby participating in the normal development and function maintaining of tissues. Some research found that ERα is expressed in about 70% of breast cancer, and its binding to estrogen may promote the proliferation and metastasis of cancer cells. However, endocrine therapy drugs can inhibit tumor growth by blocking the binding or reducing estrogen production, so ERα positive expression is closely related to the good prognosis of patients. In summary, ERα has guiding significance for the diagnosis, treatment, and prognosis of estrogen target organ tumors such as breast cancer, ovarian cancer, and endometrial cancer. In addition, ERα can be expressed in some non-estrogen target organ tumors, but its prognostic value is still controversial. For example, the high expression of ERα suggests better prognosis of liver cancer patients, but it can promote cancer cell proliferation and metastasis in gastric cancer.

MY007 | MyR1-ER

View Details

CD3

CD3 is a multimeric protein complex on the surface of T lymphocytes. Its non-covalent binding to T cell receptor (TCR) can stabilize TCR structure and transmit activation information, ensuring the normal operation of T cell antigen recognition and signal transduction. In clinical practice, CD3 can be used as a diagnostic biomarker for various tumors such as anaplastic large cell lymphoma, angioimmunoblastic T cell lymphoma, and extranodal NK/T-cell lymphoma. Meanwhile, the combination of CD2, CD3, CD5, and CD7 has reference significance for differentiating between reactive lymphoid hyperplasia (RLH) and peripheral T cell lymphoma (PTCL), which is because they are fully expressed in RLH but partially or completely absent in PTCL. Moreover, CD3 and CD20 co-expressed T cells were found in some large cell lymphomas, speculated that they are related to the pathogenesis of PTCL. In addition, some scholars suggested that multiple myeloma patients with CD3+ T lymph nodes and an increased proportion of CD3+ T cells have better prognosis.

MY017 | MyR1-CD3

View Details

PR

Progesterone receptor (PR) is a member of the steroid hormone receptor family. Its binding to progesterone can regulate the growth and development of various organs such as breast, uterus, ovary, and placenta, which will maintain the normal function of the reproductive system. Oncological research found that PR is expressed in about 70% of breast cancer, which depends on the positive regulation mediated by the binding of estrogen and its receptor (ER). Meanwhile, some studies have shown that estrogen can promote the proliferation and metastasis of cancer cells, but endocrine therapy drugs can inhibit tumor growth by inhibiting estrogen production or blocking estrogen binding to ER. Therefore, the positive expression of PR, which is considered to be the signal of estrogen binding to ER, is closely related to the good prognosis of patients. In summary, the combination of PR and ER has important clinical significance for the diagnosis, treatment, and prognosis of breast cancer, endometrial cancer and other cancers. However, the relationship between PR and tumor growth is currently inconclusive.

MY025 | MyM1-PR

View Details

CD20

CD20 is a phosphorylated glycoprotein that is widely present on the surface of B lymphocytes at various developmental stages except plasma cells, and plays an important role in their normal proliferation and differentiation. As a specific biomarker of B cells, CD20 has good diagnostic value in diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and other B cell lymphomas. However, some research found that there may be CD20 deficiency caused by MS4A1 gene mutation in DLBCL, which has higher invasiveness and poorer prognosis. Meanwhile, 5% to 8% of T cell lymphomas can express CD20, which may be caused by chromosomal translocation or progenitor cell malignant transformation. Some scholars also pointed out that CD20 can be expressed in multiple myeloma, but the specific mechanism is still unclear. In summary, the effect of CD20 in different tumors needs further analysis. In addition, CD20 positive melanoma stem cells are considered as the root cause of tumor occurrence and development.

MY027 | MyM1-CD20

View Details

P53

P53 is a transcription factor encoded by the tumor suppressor gene TP53. After receiving DNA damage signals, it can rapidly induce the production of cyclin dependent kinase inhibitor (CKI) to prevent the progression of the cell cycle and buy time for DNA repairing. If the damage is over-severe, it can also activate the apoptotic pathway to clear defective cells. However, some research has found that the TP53 gene can mutate in various solid tumors, which can express mutant P53 protein. The protein not only will lose tumor suppressive function, but may also have gain of function (GOF) activity, which can further enhance the invasiveness and drug resistance of cancer cells. Therefore, P53 is a crucial biomarker for detecting TP53 gene mutation in clinical practice, and its expression results have important reference significance for the prognosis evaluation of lung cancer, liver cancer, gastric cancer, colorectal cancer, breast cancer, osteosarcoma and other tumors.

MY081 | MyM1-p53

View Details

HER2

Human epidermal growth factor receptor 2 (HER2) is a transmembrane protein with tyrosine kinase activity in the epidermal growth factor receptor (EGFR) family. HER2 has no known natural ligand, but it can form heterodimer structure with other family members, activating various pathways to promote cell proliferation and inhibit apoptosis. Abnormal HER2 expression is found in about 20% of breast cancer, so HER2, together with ER, PR and Ki-67, becomes the most crucial diagnostic indicator of breast cancer. Moreover, HER2 positivity is considered as an independent risk factor for poor prognosis. It can down-regulate the tumor suppressor gene P53 by continuously activating the P13K/AKT pathway, thereby inhibiting apoptosis and increasing invasiveness. Meanwhile, HER2 expression heterogeneity is an important reference factor for treatment decision. Some research suggested that patients with its low expression have lower therapeutic reactivity to trastuzumab compared to its high expression. In addition, the research on the mechanism of HER2 in lung cancer, colorectal cancer, cervical cancer and other tumors has been gradually carried out.

MY116 | MYR1-HER2

View Details

PD-L1

Programmed cell death ligand -1 (PD-L1) is a type I transmembrane protein that widely exists in the T cell, B cell, macrophage, and dendritic cell. PD-L1 is a co-repressor for T cells. Its binding to programmed cell death ligand-1 (PD-1) will obstruct the P13K/AKT pathway, down-regulating the expression of cell survival related genes and thereby inhibiting T cell proliferation, activation, and cytokine secretion. Some research found that PD-L1 and PD-1 are highly expressed in various tumors, including gastric cancer, lung cancer, liver cancer, kidney cancer, breast cancer, ovarian cancer, and cervical cancer, which are closely related to the occurrence and development of tumors. This may be because the binding of PD-L1 in cancer cells and PD-1 in tumor infiltrating lymphocytes can reduce immune activity against tumors to trigger immune escape. Therefore, PD-1/PD-L1 blocking immunotherapy has become an important tumor therapy method. Meanwhile, PD-L1 can promote tumor angiogenesis and epithelial-mesenchymal transition (EMT), so it has reference significance for tumor grading and patient prognosis.

MY129 | MyM1-PD-L1

View Details

Full IHC Product Portfolio

One-stop Supply

Primary Antibodies

230+ pathology-grade antibodies

Secondary Antibodies

Spherical polymer enzyme labels with synchronized mouse/rabbit amplification

IHC Reagents

DAB chromogen, antibody diluent, antigen retrieval buffer, and more

Partnership Models

Flexible options to match different business stages

Free Trial

Validate before you buy

Organizations trying Myabtech reagents for the first time can apply for free trial samples.

Apply online

Pass review

Receive trial reagents

Apply for a Free Trial

OEM Solutions

Custom IHC raw materials

Flexible partnership models for customers of all sizes.

Bulk Custom Packaging

Flexible specs, lower cost, higher efficiency

Custom large / industrial-grade packaging on demand
Private-label or specified-spec production

In-Stock Sales

Order today, ship today — fast response

230+ pathology-grade antibodies in stock
Standard pack sizes, fast dispatch after order

About Us Our Capabilities

From R&D to delivery, we build end-to-end pathology IHC capabilities for laboratories worldwide.

230+

Self-developed pathology-grade primary antibodies Joint evaluation with industry pathology experts

3000+

Multi-tissue sample validation Compatible with major imported and domestic autostainers

1M+

Antibody supply in person-doses Serving 100+ global pathology partners

100%

Full lifecycle quality tracking End-to-end QC report traceability

Class 100K

Dust-free workshop safe production 15-day out-of-stock delivery guarantee

1 Complete Set

Self-developed IHC key raw materials for high-quality staining Including repair solution, primary antibody, diluent, secondary antibody, DAB, and more

Full-Range IHC Raw Material Supplier One-Stop IHC Raw Material Solutions

230+ Self-Developed Pathology-Grade Antibodies Validated with Leading Pathology Experts

Self-Developed Spherical Polymer HRP Secondary Antibody Smaller Size, Higher Binding Efficiency

Featured Products

P16

Ki-67

Estrogen Receptor α

CD3

PR

CD20

P53

HER2

PD-L1

Full IHC Product Portfolio

Primary Antibodies

Secondary Antibodies

IHC Reagents